Biogen Statistics
Total Valuation
Biogen has a market cap or net worth of $28.94 billion. The enterprise value is $33.78 billion.
| Market Cap | 28.94B |
| Enterprise Value | 33.78B |
Important Dates
The next estimated earnings date is Wednesday, November 6, 2024, before market open.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Biogen has 145.66 million shares outstanding. The number of shares has increased by 0.38% in one year.
| Shares Outstanding | 145.66M |
| Shares Change (YoY) | +0.38% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.24% |
| Owned by Institutions (%) | 89.82% |
| Float | 145.13M |
Valuation Ratios
The trailing PE ratio is 25.03 and the forward PE ratio is 12.76. Biogen's PEG ratio is 1.65.
| PE Ratio | 25.03 |
| Forward PE | 12.76 |
| PS Ratio | 2.99 |
| Forward PS | 2.99 |
| PB Ratio | 1.83 |
| P/FCF Ratio | 18.55 |
| PEG Ratio | 1.65 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.38, with an EV/FCF ratio of 21.58.
| EV / Earnings | 29.15 |
| EV / Sales | 3.49 |
| EV / EBITDA | 12.38 |
| EV / EBIT | 15.66 |
| EV / FCF | 21.58 |
Financial Position
The company has a current ratio of 2.29, with a Debt / Equity ratio of 0.42.
| Current Ratio | 2.29 |
| Quick Ratio | 1.28 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 2.30 |
| Debt / FCF | 4.26 |
| Interest Coverage | 8.12 |
Financial Efficiency
Return on equity (ROE) is 7.63% and return on invested capital (ROIC) is 6.19%.
| Return on Equity (ROE) | 7.63% |
| Return on Assets (ROA) | 5.19% |
| Return on Capital (ROIC) | 6.19% |
| Revenue Per Employee | $1.28M |
| Profits Per Employee | $153,052 |
| Employee Count | 7,570 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 1.19 |
Taxes
In the past 12 months, Biogen has paid $156.30 million in taxes.
| Income Tax | 156.30M |
| Effective Tax Rate | 11.90% |
Stock Price Statistics
The stock price has decreased by -23.23% in the last 52 weeks. The beta is -0.06, so Biogen's price volatility has been lower than the market average.
| Beta (5Y) | -0.06 |
| 52-Week Price Change | -23.23% |
| 50-Day Moving Average | 212.75 |
| 200-Day Moving Average | 224.85 |
| Relative Strength Index (RSI) | 34.66 |
| Average Volume (20 Days) | 716,057 |
Short Selling Information
The latest short interest is 2.68 million, so 1.84% of the outstanding shares have been sold short.
| Short Interest | 2.68M |
| Short Previous Month | 2.73M |
| Short % of Shares Out | 1.84% |
| Short % of Float | 1.85% |
| Short Ratio (days to cover) | 2.34 |
Income Statement
In the last 12 months, Biogen had revenue of $9.67 billion and earned $1.16 billion in profits. Earnings per share was $7.94.
| Revenue | 9.67B |
| Gross Profit | 7.39B |
| Operating Income | 2.16B |
| Pretax Income | 1.31B |
| Net Income | 1.16B |
| EBITDA | 2.73B |
| EBIT | 2.16B |
| Earnings Per Share (EPS) | $7.94 |
Balance Sheet
The company has $1.91 billion in cash and $6.66 billion in debt, giving a net cash position of -$4.75 billion or -$32.61 per share.
| Cash & Cash Equivalents | 1.91B |
| Total Debt | 6.66B |
| Net Cash | -4.75B |
| Net Cash Per Share | -$32.61 |
| Equity (Book Value) | 15.89B |
| Book Value Per Share | 109.05 |
| Working Capital | 4.00B |
Cash Flow
In the last 12 months, operating cash flow was $1.78 billion and capital expenditures -$218.80 million, giving a free cash flow of $1.57 billion.
| Operating Cash Flow | 1.78B |
| Capital Expenditures | -218.80M |
| Free Cash Flow | 1.57B |
| FCF Per Share | $10.74 |
Margins
Gross margin is 76.45%, with operating and profit margins of 22.31% and 11.98%.
| Gross Margin | 76.45% |
| Operating Margin | 22.31% |
| Pretax Margin | 13.58% |
| Profit Margin | 11.98% |
| EBITDA Margin | 28.22% |
| EBIT Margin | 22.31% |
| FCF Margin | 16.24% |
Dividends & Yields
Biogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.38% |
| Shareholder Yield | -0.38% |
| Earnings Yield | 3.99% |
| FCF Yield | 5.39% |
Analyst Forecast
The average price target for Biogen is $278.13, which is 39.97% higher than the current price. The consensus rating is "Buy".
| Price Target | $278.13 |
| Price Target Difference | 39.97% |
| Analyst Consensus | Buy |
| Analyst Count | 23 |
| Revenue Growth Forecast (5Y) | 2.14% |
| EPS Growth Forecast (5Y) | 23.90% |
Stock Splits
The last stock split was on January 18, 2001. It was a forward split with a ratio of 3:1.
| Last Split Date | Jan 18, 2001 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Biogen has an Altman Z-Score of 3.7 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.7 |
| Piotroski F-Score | 4 |